You are here

Keytruda

Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending

Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending

Fierce Pharma

non-small cell lung cancer

Flag link:

FDA Considers Label Changes for Keytruda, Opdivo and Yervoy

FDA Considers Label Changes for Keytruda, Opdivo and Yervoy

RAPS.org

immuno-oncology

Bristol-Myers Squibb

Flag link:

These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now

These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now

Motley Fool

Bristol-Myers Squibb

Flag link:

What the FDA's Hold on Three Merck Studies Means for Other Drug Makers

What the FDA's Hold on Three Merck Studies Means for Other Drug Makers

TheStreet.com

clinical trials

Multiple Myeloma

Bristol-Myers Squibb

Flag link:

Prescribed Reading: I/O is the only game in town

Prescribed Reading: I/O is the only game in town

BioPharma Dive

immuno-oncology

Endo International

Vertex Pharmaceuticals

Bristol-Myers Squibb

Flag link:

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

Endpoints

clinical trials

Multiple Myeloma

Flag link:

Personalized cancer vaccines vanquish melanoma in small but encouraging study

Personalized cancer vaccines vanquish melanoma in small but encouraging study

Stat

personalized medicine

Neon Therapeutics

Flag link:

The FDA Has Never Approved a Drug Like This in Its 111-Year History

The FDA Has Never Approved a Drug Like This in Its 111-Year History

Motley Fool

mismatch repair deficiency

Flag link:

Could Merck and Leap union be the one for Keytruda?

Could Merck and Leap union be the one for Keytruda?

TheStreet.com

Leap Therapeutics

esophagogastric cancer

Flag link:

Checkmate Pharma Clinches $27M for More Studies in Skin Cancer

Checkmate Pharma Clinches $27M for More Studies in Skin Cancer

Xconomy

Checkmate Pharmaceuticals

Flag link:

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research

Endpoints

Flag link:

Merck pauses Keytruda trials, raising concerns about class

Merck pauses Keytruda trials, raising concerns about class

BioPharma Dive

clinical trials

Flag link:

How Merck hopes to win in I/O combos: Q&A with Roy Baynes

How Merck hopes to win in I/O combos: Q&A with Roy Baynes

BioPharma Dive

immuno-oncology

Bristol-Myers Squibb

Flag link:

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

Endpoints

clinical trials

Multiple Myeloma

Flag link:

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Endpoints

Bristol-Myers Squibb

Flag link:

Why Array BioPharma Inc. Sank 13.5% in May

Why Array BioPharma Inc. Sank 13.5% in May

Motley Fool

Array Biopharma

Bristol-Myers Squibb

Flag link:

An Unprecedented FDA Approval Bodes Well for this Drug Stock

An Unprecedented FDA Approval Bodes Well for this Drug Stock

Motley Fool

Flag link:

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

BioPharma Dive

Flag link:

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

Endpoints

non-small cell lung cancer

Flag link:

How Did Bristol Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss

How Did Bristol Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss

Forbes

Bristol-Myers Squibb

Flag link: